Imviva Biotech is cleared to launch a basket Phase 1b trial testing its investigational off-the-shelf CAR T-cell therapy CTA313 in progressive multiple sclerosis (MS) and other B-cell-mediated autoimmune diseases. The announcement follows the clearance of the company’s investigational new drug (IND) application by the U.S.…
Jennifer Powell, shares how she prepares for symptom flares in public, including heat sensitivity, falls, and communication challenges. The post Managing sudden MS symptoms in public appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Susan Payrovi, MD, describes what she wishes she had taken more seriously early on in her diagnosis. The post In hindsight, therapy should have been taken more seriously with MS appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Tweet The conclusion of the paper is that there is still residual inflammation in the MS brain despite treatment with natalizumab. Buhelt et al. Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis. Front. Immunol., 05 June 2026…